Immunogenicity and protective potency of Norovirus GII.17 virus-like particle-based vaccine.

CONCLUSIONS: Together, these results suggested that GII.17 VLPs represent a promising vaccine candidate against NoV GII.17 infection and strongly support further preclinical and clinical studies. PMID: 32088791 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32088791?dopt=Abstract

Source: Biotechnology Letters - February 21, 2020 Category: Biotechnology Authors: Chen W, Kang T, Yuan R, Shao C, Jing S Tags: Biotechnol Lett Source Type: research